ARTICLE | Clinical News
ISIS-DMPKRx: Phase I started
June 30, 2014 7:00 AM UTC
Isis began a Phase I trial of ISIS-DMPKRx. The start triggered a $14 million milestone payment to Isis from Biogen Idec Inc. (NASDAQ:BIIB, Weston, Mass.) under a June 2012 deal granting Biogen Idec a...